Recursion Net Receivables from 2010 to 2025
| RXRX Stock | USD 6.55 0.24 3.53% |
Net Receivables | First Reported 2010-12-31 | Previous Quarter 49.2 M | Current Value 51.6 M | Quarterly Volatility 17 M |
Check Recursion Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Recursion Pharmaceuticals' main balance sheet or income statement drivers, such as Net Interest Income of 14.9 M, Interest Income of 16.5 M or Depreciation And Amortization of 38.3 M, as well as many indicators such as Price To Sales Ratio of 29.93, Dividend Yield of 0.0 or PTB Ratio of 1.88. Recursion financial statements analysis is a perfect complement when working with Recursion Pharmaceuticals Valuation or Volatility modules.
Recursion | Net Receivables |
Latest Recursion Pharmaceuticals' Net Receivables Growth Pattern
Below is the plot of the Net Receivables of Recursion Pharmaceuticals over the last few years. It is Recursion Pharmaceuticals' Net Receivables historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Recursion Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
| Net Receivables | 10 Years Trend |
|
Net Receivables |
| Timeline |
Recursion Net Receivables Regression Statistics
| Arithmetic Mean | 7,337,081 | |
| Geometric Mean | 585,152 | |
| Coefficient Of Variation | 231.33 | |
| Mean Deviation | 10,983,632 | |
| Median | 151,000 | |
| Standard Deviation | 16,972,668 | |
| Sample Variance | 288.1T | |
| Range | 51.5M | |
| R-Value | 0.63 | |
| Mean Square Error | 186.1T | |
| R-Squared | 0.40 | |
| Significance | 0.01 | |
| Slope | 2,246,593 | |
| Total Sum of Squares | 4321.1T |
Recursion Net Receivables History
About Recursion Pharmaceuticals Financial Statements
Recursion Pharmaceuticals investors use historical fundamental indicators, such as Recursion Pharmaceuticals' Net Receivables, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Recursion Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Net Receivables | 49.2 M | 51.6 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| ZLAB | Zai Lab | |
| ASLE | AerSale Corp | |
| ATS | AT S Austria |
Additional Tools for Recursion Stock Analysis
When running Recursion Pharmaceuticals' price analysis, check to measure Recursion Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Recursion Pharmaceuticals is operating at the current time. Most of Recursion Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Recursion Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Recursion Pharmaceuticals' price. Additionally, you may evaluate how the addition of Recursion Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.